Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Oxford BioTherapeutics

Request full access

Clinical-stage oncology antibody-based cancer therapies developer

Oxford, United KingdomFounded 2004Biotech & Life Sciences

About Oxford BioTherapeutics

Oxford BioTherapeutics is a clinical-stage oncology company that develops antibody-based therapies for cancer patients. The company was founded in 2004 by Dr. Christian Rohlff, who serves as the CEO. Dr. Rohlff has over two decades of experience in the international biotechnology industry, having held positions at the US National Cancer Institute and Oxford Glycosciences.

The company's core technology is its proprietary OGAP® target discovery platform. OGAP® is one of the world's largest proteomic databases, containing information on thousands of cancer cell proteins, which allows for the identification of novel oncology targets. This platform has enabled the development of a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies. These therapies include bispecifics, Chimeric Antigen Receptor T Cell (CAR-T), and Antibody Dependent Cell-mediated Cytotoxicity (ADCC) therapeutics. The company's business model is centered on leveraging its OGAP® platform to discover novel cancer targets and then collaborating with major pharmaceutical companies for further development and commercialization. These partnerships typically involve upfront payments, milestone payments, and royalties on net sales. Oxford BioTherapeutics has established strategic collaborations with companies like Roche, Boehringer Ingelheim, Genmab, Kite Pharma, and ImmunoGen.

One of its lead clinical programs is OBT076, an ADC that entered a U.S. clinical trial in 2021 for patients with advanced or refractory solid tumors such as gastric, bladder, ovarian, and lung cancer. The company operates from its headquarters in Oxford, UK, and has a presence in San Jose, California. In October 2023, it relocated its UK headquarters to The Oxford Science Park to be at the center of the Oxford biotech ecosystem.

Source: Dealroom company data

Oxford BioTherapeutics in the Oxford ecosystem

Live from Dealroom

The Oxford BioTherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Oxford Capital
  • South East Growth Fund & Management
  • Calculus Capital

Series B and later2 investors entered at this stage

  • Standard Treasury
  • Oxford Finance
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇬🇧 United Kingdom32.1%
🇨🇭 Switzerland1.8%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Oxford BioTherapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Oxford BioTherapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.